We propose a clinician-facing three-panel workflow: Panel A standardizes initial evaluation and mandates germline RET testing for all patients; Panel B outlines genotype- and staging-informed surgery and surveillance for hereditary disease, including pediatric carriers; and Panel C provides a staged approach for sporadic MTC in which imaging directs compartment selection and early postoperative DSR and biochemical response tailor surveillance intensity and thresholds for re-staging and re-intervention. Here, RET is linked to medullary thyroid gland carcinoma.